Status:
COMPLETED
Early Diagnostic of Sepsis and Potential Impact on Antibiotic Management Based on Serial.Pancreatic Stone Protein (PSP) Measured Using the AbioScope.
Lead Sponsor:
Abionic SA
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Brief Summary
The main purpose of this study is to compare the early detection of sepsis and the decision, by the Investigator to start or not, or to change, antibiotics in Intensive Care Unit (ICU) patients at hig...
Eligibility Criteria
Inclusion
- Adult patients (age ≥ 18 years)
- Requiring ICU management
- At high risk of sepsis (septic patients are excluded)
- Expected ICU stay for more than 4 days
- Have provided written informed consent or consent is given by the patient's legally designated representative.
Exclusion
- Patient expected to die within 48 hours of admission to ICU
- Patient suffering from or known acute or chronic pancreatitis, pancreatic cancer or admitted after pancreatectomy, but if a patient develops any pancreatic disease during the IUC stay he/she will remain in the study.
Key Trial Info
Start Date :
June 14 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 15 2019
Estimated Enrollment :
296 Patients enrolled
Trial Details
Trial ID
NCT03474809
Start Date
June 14 2018
End Date
March 15 2019
Last Update
August 13 2019
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
CH Le Mans, Service de Réanimation Médico Chirurgicale & USC
Le Mans, France, 72037
2
CHU Limoges, Réanimation Polyvalente
Limoges, France, 87042
3
CH Lyon-Sud, Services de soins critiques
Pierre-Bénite, France, 69495
4
Hôpital Bretonneau, CHU de Tours, Médecine Intensive - Réanimation
Tours, France, 37044